. Author manuscript; available in PMC: 2020 Dec 1.

Published in final edited form as: Arthritis Rheumatol. 2019 Nov 1;71(12):2059–2067. doi: 10.1002/art.41020

Table 4.

High baseline CCL-18 predicts progression of ILD based on the course of the FVC and DL_CO over 1 year in patients randomized to CYC and MMF.

Variable	Estimate	95% CI		P-Value
Outcome: Course of FVC over 12 months in CYC arm

Intercept	13.80	11.92	15.65	<0.001
CCL-18	−1.24	−1.46	−1.03	<0.001
Baseline FVC	0.91	0.90	0.93	<0.001
Time	0.10	0.025	0.17	0.012

Outcome: Course of FVC over 12 months in MMF arm

Intercept	10.21	8.34	11.89	<0.001
CCL-18	−0.35	−0.52	−0.16	0.007
Baseline FVC	0.88	0.86	0.90	<0.001
Time	0.057	−0.014	0.13	0.114

Outcome: Course of DL_CO over 12 months in CYC arm

Intercept	16.91	12.16	19.61	<0.001
CCL-18	−1.87	−2.17	−1.19	0.001
Baseline DL_CO	0.87	0.84	0.89	<0.001
Time	−0.020	−0.11	0.065	0.642

Outcome: Course of DL_CO over 12 months in MMF arm

Intercept	17.36	14.39	19.45	<0.001
CCL-18	−1.25	−1.49	−0.92	<0.001
Baseline DL_CO	0.85	0.82	0.87	<0.001
Time	0.040	−0.040	0.12	0.327